XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2022
Sep. 30, 2022
Current Assets:    
Cash and cash equivalents $ 36,887,251 $ 41,711,690
Prepaid expenses 5,430,125 2,852,580
Total Current Assets 42,317,376 44,564,270
Property and equipment, net 3,370 4,100
Operating lease right-of-use asset, net 599,617 646,074
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 111,705,221 113,999,302
Current Liabilities:    
Accounts payable 1,537,578 1,165,378
Accrued expenses 690,402 1,405,394
Accrued compensation 2,107,014 1,762,251
Operating lease liability 202,178 196,989
Total Current Liabilities 4,537,172 4,530,012
Deferred tax liability 5,705,800 5,561,800
Operating lease liability – noncurrent 428,568 481,245
Total Liabilities 10,671,540 10,573,057
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 146,211,130 shares issued and outstanding at December 31, 2022 and September 30, 2022 146,211 146,211
Additional paid-in capital 233,569,202 232,368,121
Accumulated deficit (133,282,112) (129,688,467)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 100,433,301 102,825,865
Non-controlling interest 600,380 600,380
Total Equity 101,033,681 103,426,245
Total Liabilities and Equity $ 111,705,221 $ 113,999,302